Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
05 2021
Historique:
received: 05 10 2020
accepted: 16 04 2021
revised: 28 05 2021
pubmed: 19 5 2021
medline: 15 9 2021
entrez: 18 5 2021
Statut: epublish

Résumé

Like many other types of cancer, colorectal cancer (CRC) develops through multiple pathways of carcinogenesis. This is also true for colorectal carcinogenesis in Lynch syndrome (LS), the most common inherited CRC syndrome. However, a comprehensive understanding of the distribution of these pathways of carcinogenesis, which allows for tailored clinical treatment and even prevention, is still lacking. We suggest a linear dynamical system modeling the evolution of different pathways of colorectal carcinogenesis based on the involved driver mutations. The model consists of different components accounting for independent and dependent mutational processes. We define the driver gene mutation graphs and combine them using the Cartesian graph product. This leads to matrix components built by the Kronecker sum and product of the adjacency matrices of the gene mutation graphs enabling a thorough mathematical analysis and medical interpretation. Using the Kronecker structure, we developed a mathematical model which we applied exemplarily to the three pathways of colorectal carcinogenesis in LS. Beside a pathogenic germline variant in one of the DNA mismatch repair (MMR) genes, driver mutations in APC, CTNNB1, KRAS and TP53 are considered. We exemplarily incorporate mutational dependencies, such as increased point mutation rates after MMR deficiency, and based on recent experimental data, biallelic somatic CTNNB1 mutations as common drivers of LS-associated CRCs. With the model and parameter choice, we obtained simulation results that are in concordance with clinical observations. These include the evolution of MMR-deficient crypts as early precursors in LS carcinogenesis and the influence of variants in MMR genes thereon. The proportions of MMR-deficient and MMR-proficient APC-inactivated crypts as first measure for the distribution among the pathways in LS-associated colorectal carcinogenesis are compatible with clinical observations. The approach provides a modular framework for modeling multiple pathways of carcinogenesis yielding promising results in concordance with clinical observations in LS CRCs.

Identifiants

pubmed: 34003820
doi: 10.1371/journal.pcbi.1008970
pii: PCOMPBIOL-D-20-01806
pmc: PMC8162698
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008970

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Gastroenterology. 2020 Apr;158(5):1326-1333
pubmed: 31926173
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Hum Mutat. 1993;2(6):425-34
pubmed: 8111410
Biochim Biophys Acta. 2015 Apr;1855(2):264-75
pubmed: 25827356
Br J Cancer. 1954 Mar;8(1):1-12
pubmed: 13172380
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Pathol. 2017 Oct;243(2):242-254
pubmed: 28727142
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Oncotarget. 2017 Nov 14;8(64):108020-108030
pubmed: 29296220
J Theor Biol. 2003 Aug 21;223(4):433-50
pubmed: 12875822
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Expert Rev Gastroenterol Hepatol. 2016;10(3):277-9
pubmed: 26690852
Fam Cancer. 2016 Oct;15(4):579-86
pubmed: 26960970
Genome Biol. 2015 Aug 08;16:160
pubmed: 26253137
Hered Cancer Clin Pract. 2019 Feb 28;17:8
pubmed: 30858900
Cell. 1996 Oct 18;87(2):159-70
pubmed: 8861899
Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Science. 2017 Jul 07;357(6346):55-60
pubmed: 28684519
Trends Genet. 1993 Apr;9(4):138-41
pubmed: 8516849
J Comput Biol. 1999 Spring;6(1):37-51
pubmed: 10223663
Int J Epidemiol. 2007 Feb;36(1):246-7
pubmed: 17169945
Nat Genet. 2020 Oct;52(10):1057-1066
pubmed: 32929288
PLoS One. 2015 Mar 27;10(3):e0121980
pubmed: 25816162
EMBO J. 2015 Sep 14;34(18):2321-33
pubmed: 26240067
Neoplasia. 2008 Nov;10(11):1170-82
pubmed: 18953426
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20681-20688
pubmed: 32788368
Genetics. 2004 Mar;166(3):1571-9
pubmed: 15082570
Int J Epidemiol. 2005 Oct;34(5):1168-70
pubmed: 16046521
Gastroenterology. 2014 Mar;146(3):602-4
pubmed: 24468183
bioRxiv. 2020 Dec 18;:
pubmed: 33442687
BMC Cancer. 2020 Oct 28;20(1):1038
pubmed: 33115416
Expert Rev Mol Diagn. 2005 Jul;5(4):599-611
pubmed: 16013977
Gut. 2019 Nov;68(11):1986-1993
pubmed: 30872394
J Pathol. 2016 Jan;238(1):98-108
pubmed: 26414517
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23
pubmed: 25535351
Br J Cancer. 1957 Jun;11(2):161-9
pubmed: 13460138
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31
pubmed: 12446840
Nat Commun. 2020 Feb 25;11(1):1035
pubmed: 32098957
Cell Rep. 2014 Aug 21;8(4):940-7
pubmed: 25127143
N Engl J Med. 2003 Jul 17;349(3):209-10
pubmed: 12867603
Cancer Res. 1999 Apr 15;59(8):1857-60
pubmed: 10213492
Int J Cancer. 2021 Feb 15;148(4):800-811
pubmed: 32683684
Surg Radiol Anat. 2002 Dec;24(5):290-4
pubmed: 12497219
Bioinformatics. 2009 Nov 1;25(21):2809-15
pubmed: 19692554
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
pubmed: 5279523
Cell Stem Cell. 2018 Jun 01;22(6):909-918.e8
pubmed: 29779891
Lancet Oncol. 2012 Jun;13(6):598-606
pubmed: 22552011
Genes Dev. 1996 Jun 15;10(12):1433-42
pubmed: 8666228
J Comput Biol. 2005 Jul-Aug;12(6):584-98
pubmed: 16108705
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
Heredity (Edinb). 2020 Jan;124(1):50-61
pubmed: 31515531
Int J Cancer. 2001 Jul 1;93(1):12-9
pubmed: 11391615
Trends Cancer. 2016 Mar;2(3):121-133
pubmed: 28741532
Clin Colon Rectal Surg. 2009 Nov;22(4):198-208
pubmed: 21037810
World J Gastroenterol. 2007 Mar 7;13(9):1399-407
pubmed: 17457972
Gut. 2018 Jul;67(7):1306-1316
pubmed: 28754778
Cell Prolif. 2006 Jun;39(3):157-81
pubmed: 16671995
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Cell. 2018 Apr 19;173(3):611-623.e17
pubmed: 29656891
Cancer Biol Ther. 2002 Nov-Dec;1(6):685-92
pubmed: 12642695
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Gastroenterol. 2001 Jun;96(6):1901-7
pubmed: 11419846
Gastroenterology. 2018 Nov;155(5):1400-1409.e2
pubmed: 30063918
Am J Clin Pathol. 2003 Jun;119(6):778-96
pubmed: 12817424
Nucleic Acids Res. 2016 Jan 4;44(D1):D733-45
pubmed: 26553804
Gastroenterology. 2010 Jun;138(6):2044-58
pubmed: 20420945
Int J Cancer. 2018 Jul 1;143(1):139-150
pubmed: 29424427
Nat Commun. 2020 Sep 21;11(1):4740
pubmed: 32958755

Auteurs

Saskia Haupt (S)

Engineering Mathematics and Computing Lab (EMCL), Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany.
Data Mining and Uncertainty Quantification (DMQ), Heidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany.

Alexander Zeilmann (A)

Image and Pattern Analysis Group (IPA), Heidelberg University, Heidelberg, Germany.

Aysel Ahadova (A)

Department of Applied Tumor Biology (ATB), Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Hendrik Bläker (H)

Institute of Pathology, University Hospital Leipzig, Leipzig, Germany.

Magnus von Knebel Doeberitz (M)

Department of Applied Tumor Biology (ATB), Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Matthias Kloor (M)

Department of Applied Tumor Biology (ATB), Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Vincent Heuveline (V)

Engineering Mathematics and Computing Lab (EMCL), Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany.
Data Mining and Uncertainty Quantification (DMQ), Heidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH